CRISPR Gene Editing in Doylestown, Pennsylvania

GeneLancet,  established in NOV 2019, is a biotechnology company developing in vivo gene and cell therapy.

The company owns distinct intellectual property covering a novel single-molecule guide RNA (LgRNA) that enhances all CRISPR gene editors and develops LgRNA conjugate-guided precise genome editors, including DuoSTAR Editors (segNA-directed polymerase editors), for biological and therapeutic applications.

The company is advancing curative treatments for cancers, chronic hepatitis B, and other serious diseases of clear genetic causes.